-
1.发明申请公开(公告)号：US20160193324A1
公开(公告)日：2016-07-07
申请号：US14916458
申请日：2014-09-02
申请人： Brian K. MEYER , Robert K. EVANS , Channing R. BEALS , David C. KASLOW , Merck Sharp & Dohme Corp.
IPC分类号： A61K39/25 , A61K39/145 , A61K39/165 , A61K39/102 , A61K39/05 , A61K39/08 , A61K39/02 , A61K39/13 , C12N7/00 , A61K39/20
CPC分类号： A61K39/25 , A61K39/05 , A61K39/08 , A61K39/099 , A61K39/102 , A61K39/12 , A61K39/13 , A61K39/145 , A61K39/165 , A61K39/20 , A61K2039/5252 , A61K2039/5254 , A61K2039/54 , A61K2039/55 , C12N7/00 , C12N2710/16734 , C12N2760/16034 , C12N2760/18434 , C12N2770/32634 , C12N2770/36234
摘要： The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.
摘要翻译： 本发明涉及一种通过将有效量的活减毒VZV疫苗递送至患者皮肤的表皮或真皮的约100至约700埃的深度来接种患者抗水痘带状疱疹病毒（VZV）的方法 从皮肤表面微米，其可用于预防带状疱疹或降低其严重性或持续时间。 在本发明的实施方案中，患者为50岁或以上，并且先前已经暴露于VZV。 本发明还涉及一种在先前未感染VZV的个体中预防VZV感染的方法，其包括以约100至约100的浓度施用有效量的活减毒VZV疫苗至个体皮肤的表皮或真皮， 距离皮肤表面约700微米。
-
公开(公告)号：US10350289B2
公开(公告)日：2019-07-16
申请号：US14916458
申请日：2014-09-02
IPC分类号： A61K39/165 , C12N7/00 , A61K39/25 , A61K39/12 , A61K39/05 , A61K39/08 , A61K39/02 , A61K39/102 , A61K39/13 , A61K39/145 , A61K39/20 , A61K39/00
摘要： The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.
-
公开(公告)号：US07407658B2
公开(公告)日：2008-08-05
申请号：US11611779
申请日：2006-12-15
申请人： David C. Kaslow , Takafumi Tsuboi , Motomi Torii
发明人： David C. Kaslow , Takafumi Tsuboi , Motomi Torii
IPC分类号： A61K39/00 , A61K39/015
CPC分类号： A61K39/015 , C07K16/205 , Y02A50/412
摘要： The present invention relates novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
摘要翻译： 本发明涉及用于阻断疟原虫的间日疟原虫传播的新方法和组合物。 特别地，公开了Pvs25和Pvs28多肽，变体，包括去糖基化形式及其融合蛋白，其当被施用于易感生物体时分别在疟原虫表面上诱导针对25kD和28kD蛋白的免疫应答 间日ax z和ookinetes。 易感生物体内的这种免疫应答可以阻止疟疾传播。
-
4.发明授权Cloning and expression of plasmodium falciparum transmission-blocking target antigen, PFS230 失效恶性疟原虫传播阻断靶抗原PFS230的克隆和表达公开(公告)号：US06316000B1
公开(公告)日：2001-11-13
申请号：US08954441
申请日：1997-10-20
申请人： Kim C. Williamson , David C. Kaslow
发明人： Kim C. Williamson , David C. Kaslow
IPC分类号： A61K39015
CPC分类号： C07K14/445 , A61K39/00 , Y02A50/412
摘要： Compositions comprising biologically pure Pfs230 and nucleic acids which encode them are provided. The proteins can be used induce transmission blocking immune responses in susceptible hosts.
摘要翻译： 提供了包含生物纯的Pfs230和编码它们的核酸的组合物。 可以使用蛋白质诱导易感宿主中的传播阻断免疫应答。
-
公开(公告)号：US08530234B2
公开(公告)日：2013-09-10
申请号：US12633104
申请日：2009-12-08
申请人： David C. Kaslow , Andrew J. Bett
发明人： David C. Kaslow , Andrew J. Bett
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
-
公开(公告)号：US08142794B2
公开(公告)日：2012-03-27
申请号：US12396747
申请日：2009-03-03
申请人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
发明人： Emilio A. Emini , David C. Kaslow , Andrew J. Bett , John W. Shiver , Alfredo Nicosia , Armin Lahm , Alessandra Luzzago , Riccardo Cortese , Stefano Colloca
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译： 本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。 核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。
-
7.发明申请Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby 审中-公开腺病毒血清型26载体，核酸和由此产生的病毒公开(公告)号：US20080254059A1
公开(公告)日：2008-10-16
申请号：US11884086
申请日：2006-02-07
申请人： Andrew J. Bett , Danilo R. Casimiro , John W. Shiver , Emilio A. Emini , Michael Chastain , David C. Kaslow
发明人： Andrew J. Bett , Danilo R. Casimiro , John W. Shiver , Emilio A. Emini , Michael Chastain , David C. Kaslow
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/54 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N2710/10321 , C12N2710/10343 , C12N2740/16134 , C12N2740/16234 , C12N2740/16334
摘要： Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 26, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for delivery and expression of heterologous genes are provided.
摘要翻译： 腺病毒血清型的自然向性不同。 已经发现各种各样的腺病毒血清型在至少它们的衣壳蛋白（例如，五邻体和六邻体蛋白），负责细胞结合的蛋白质（例如纤维蛋白）和参与腺病毒复制的蛋白质中不同。 血清型中的向性和衣壳蛋白的这种差异导致了许多研究工作，旨在通过修饰衣壳蛋白来重新定向腺病毒向性。 本发明绕过这样的衣壳蛋白修饰的要求，因为它呈现血清型26的重组复制缺陷型腺病毒，罕见的腺病毒血清型，以及产生替代重组腺病毒的方法。 另外，提供了使用重组腺病毒递送和表达异源基因的方法。
-
公开(公告)号：US07192934B1
公开(公告)日：2007-03-20
申请号：US09554960
申请日：1998-12-04
申请人： David C. Kaslow , Takafumi Tsuboi , Motomi Torii
发明人： David C. Kaslow , Takafumi Tsuboi , Motomi Torii
CPC分类号： A61K31/70 , A61K39/002 , C07K14/445 , Y02A50/412
摘要： The present invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.
摘要翻译： 本发明涉及用于阻断疟原虫的间日疟原虫传播的新方法和组合物。 特别地，公开了Pvs25和Pvs28多肽，变体，包括去糖基化形式及其融合蛋白，其当被施用于易感生物体时分别在疟原虫表面上诱导针对25kD和28kD蛋白的免疫应答 间日ax z和ookinetes。 易感生物体内的这种免疫应答可以阻止疟疾传播。
-
公开(公告)号：US5853739A
公开(公告)日：1998-12-29
申请号：US365997
申请日：1994-12-29
申请人： David C. Kaslow , Philip J. Barr
发明人： David C. Kaslow , Philip J. Barr
IPC分类号： A61K38/00 , A61K39/00 , C07K14/445 , C12N15/86 , A61K39/015 , C12N15/00 , C12N7/00 , C12P21/02
CPC分类号： C07K14/445 , A61K38/00 , A61K39/00 , C07K2319/02 , C12N2710/24143
摘要： The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.
摘要翻译： 本发明涉及抗疟疾传播阻断疫苗。 本发明的疫苗含有由酵母细胞产生的重组Pfs25恶性疟原虫蛋白质和产生蛋白质的酵母细胞。 用本发明的酵母表达的Pfs25接种的小鼠和猴已经开发了具有传递阻断活性的抗体。 本发明还涉及使用本发明的疫苗预防或治疗疟疾感染的方法。
-
公开(公告)号：US20100129901A1
公开(公告)日：2010-05-27
申请号：US12633104
申请日：2009-12-08
申请人： David C. Kaslow , Andrew J. Bett
发明人： David C. Kaslow , Andrew J. Bett
CPC分类号： C07K14/005 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C12N15/86 , C12N2710/10343 , C12N2770/24222 , C12N2770/24234 , C12N2800/108 , C12N2810/6018 , C12N2830/003 , C12N2840/20 , C12N2840/203
摘要： The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
摘要翻译： 本发明的特征在于Ad6载体和编码含有非活性NS5B RNA依赖性RNA聚合酶区域的Met-NS3-NS4A-NS4B-NS5A-NS5B多肽的核酸。 核酸特别可用作腺病毒或DNA质粒疫苗的组分，其提供用于产生针对HCV的HCV特异性细胞介导的免疫（CMI）应答的广泛范围的抗原。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.037 秒)
